Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Joly-Guillou, M. L.
Right arrow Articles by Carbon, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joly-Guillou, M. L.
Right arrow Articles by Carbon, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 827-830
© 2000 The British Society for Antimicrobial Chemotherapy

Brief report

In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia

M. L. Joly-Guilloua, M. Wolffb, R. Farinottic, A. Bryskierd and C. Carbone

a Service de Microbiologie, Hôpital Louis Mourier, 92701 Colombes; b Clinique de de Réanimation des Maladies Infectieuses; c Service de Pharmacie and e EPI 99 33, Hôpital Bichat-Claude Bernard, 75018 Paris; and d Hoechst Marion Roussel, 92000 Romainville, France

We evaluated the in vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia using a susceptible strain and one with low-level resistance (MIC/MBC of levofloxacin: 0.06/0.06 and 4/4 mg/L, respectively). As demonstrated previously with other pathogens, the AUC/MIC ratio predicted the efficacy of fluoroquinolones against A. baumannii. This parameter correlated with bactericidal effect and survival. Combination therapy did not enhance the efficacy of levofloxacin.

* Corresponding author. Tel: +33-1-4760-6012; Fax: +33-1-4760-6048.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
T. A. Russo, J. M. Beanan, R. Olson, U. MacDonald, N. R. Luke, S. R. Gill, and A. A. Campagnari
Rat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology
Infect. Immun., August 1, 2008; 76(8): 3577 - 3586.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. Y. Peleg, H. Seifert, and D. L. Paterson
Acinetobacter baumannii: Emergence of a Successful Pathogen
Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3471 - 3484.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. Jain and L. H Danziger
Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians
Ann. Pharmacother., September 1, 2004; 38(9): 1449 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, and F. Gudiol
Efficacy of Colistin versus {beta}-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1946 - 1952.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.